A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment

AIMS: To assess the safety and efficacy of omarigliptin in subjects with type 2 diabetes mellitus (T2DM) and chronic renal impairment (RI). METHODS: Patients with T2DM with moderate RI (estimated glomerular filtration rate [eGFR] ≥30 to <60 mL/min/1.73 m(2)) (N=114), severe RI (eGFR <30 mL/min...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J Clin Pract
Hoofdauteurs: Chacra, Antonio, Gantz, Ira, Mendizabal, Geraldine, Durlach, Lucila, O'Neill, Edward A., Zimmer, Zachary, Suryawanshi, Shailaja, Engel, Samuel S., Lai, Eseng
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2017
Onderwerpen:
Original Papers
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681174/
https://ncbi.nlm.nih.gov/pubmed/28449320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12955
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items